Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era.

Jordan B Fenlon, Ryan J Hutten, Skyler B Johnson, Boyu Hu, Harsh Shah, Deborah M Stephens, Amit Maity, David K Gaffney, Randa Tao

Leukemia & lymphoma 2023 Feb

filter terms:

Radiotherapy (RT) utilization for early-stage, low-grade follicular lymphoma (FL) is low despite treatment guideline recommendations. We compare treatment trends for early-stage FL in the era of involved-site RT and rituximab. We identified 11,645 patients in the National Cancer Database (NCDB) with stage I-II, grade 1-2 nodal or extranodal FL diagnosed 2011-2017, with median follow-up of 44 months. From 2011 to 2017, RT utilization rates decreased from 33.4% to 22.4%, observation decreased from 65.3% to 49.7%, chemoimmunotherapy increased from 0.5% to 15.0%, immuno-monotherapy increased from 0.6% to 10.2%, and RT + systemic therapy increased from 0.6% to 2.5%. RT utilization remains low in the involved-site RT and rituximab era.

Citation

Jordan B Fenlon, Ryan J Hutten, Skyler B Johnson, Boyu Hu, Harsh Shah, Deborah M Stephens, Amit Maity, David K Gaffney, Randa Tao. Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leukemia & lymphoma. 2023 Feb;64(2):356-363